Portland, OR, United States of America

Andy Weinberg

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Andy Weinberg in Cancer Treatment

Introduction

Andy Weinberg is a notable inventor based in Portland, OR (US), recognized for his significant contributions to cancer treatment methodologies. With a focus on immune stimulation, his work has the potential to enhance the clinical outcomes for cancer patients.

Latest Patents

Weinberg holds a patent for "Cancer treatment and monitoring methods using OX40 agonists." This innovative approach utilizes OX40, a potent immune-stimulating target, to develop methods for treating cancer patients. His patent outlines techniques to predict the clinical outcomes of treatment by correlating the treatment with an increase in OX40-induced T cell proliferation. This advancement represents a promising avenue in cancer therapy.

Career Highlights

Andy Weinberg is affiliated with Providence Health & Services - Oregon, where he applies his expertise in developing cutting-edge cancer treatment strategies. His work is instrumental in pushing the boundaries of current medical practices and improving patient care.

Collaborations

Weinberg collaborates with esteemed colleagues, including Brendan Curti and Magdalena Kovacsovics-Bankowski, who contribute to the research and development of innovative cancer therapies. Their combined efforts enhance the potential for breakthroughs in the field.

Conclusion

In summary, Andy Weinberg's innovative work in cancer treatment through OX40 agonists showcases his commitment to advancing medical science. His contributions are paving the way for improved therapeutic strategies in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…